Get the latest news, insights, and market updates on ACIU (AC Immune SA). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Top Penny Stocks To Watch In January 2026
As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in... Jan 13, 2026 - $ACIU
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks
As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are keenly observing potential opportunities across various sectors. While large-cap stocks often dominate headlines, penny stocks—typically smaller or newer companies—continue to pique interest due to their potential for significant returns when backed by solid financials. Despite being considered a relic of past trading days, penny stocks still offer intriguing prospects... Dec 12, 2025 - $ACIU
AC Immune posts positive data for Parkinson’s immunotherapy
Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug regulators for feedback to “potentially accelerate” the time to an approval filing. Dec 11, 2025 - $ACIU
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s diseaseClear safety profile with no clinically relevant safety issues reportedTargets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessmentsUnderlines potential and im Dec 11, 2025 - $ACIU
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on Nove Nov 11, 2025 - $ACIU
AC Immune (ACIU): Losses Narrow 5.9% Annually; Revenue Growth Forecast at 55.6% Pre-Earnings
AC Immune (ACIU) remains unprofitable, but has managed to shrink its losses by an average of 5.9% per year over the last five years. With consensus forecasts calling for annual earnings growth of 66.51% and a transition to profitability expected within three years, the numbers position the company as a high-growth biotech. Revenue is projected to climb 55.6% annually. The current Price-to-Book Ratio of 4.2x stands out above peers and the US Biotech industry average. Investors are likely to... Nov 5, 2025 - $ACIU
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple